Horizon Therapeutics Past Earnings Performance
Past criteria checks 1/6
Horizon Therapeutics has been growing earnings at an average annual rate of 32.8%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 28.5% per year. Horizon Therapeutics's return on equity is 8.2%, and it has net margins of 12%.
Key information
32.8%
Earnings growth rate
30.0%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 28.5% |
Return on equity | 8.2% |
Net Margin | 12.0% |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely
Nov 25Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?
Nov 02Horizon pays HemoShear milestone payment under pact to develop gout therapies
Sep 21Horizon Therapeutics announces $500M buyback program
Sep 09Horizon Therapeutics to expand footprint in Ireland
Aug 29Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?
Aug 22Horizon Therapeutics: This Core Biotech Company Is On Sale
Aug 19Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)
Aug 04Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?
Aug 02Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth
Jul 31Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout
Jul 08Revenue & Expenses Breakdown
How Horizon Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 3,644 | 438 | 1,659 | 516 |
31 Mar 23 | 3,576 | 372 | 1,623 | 469 |
31 Dec 22 | 3,629 | 521 | 1,543 | 438 |
30 Sep 22 | 3,701 | 574 | 1,592 | 422 |
30 Jun 22 | 3,813 | 765 | 1,526 | 354 |
31 Mar 22 | 3,769 | 862 | 1,511 | 391 |
31 Dec 21 | 3,226 | 534 | 1,442 | 345 |
30 Sep 21 | 2,957 | 552 | 1,297 | 315 |
30 Jun 21 | 2,557 | 518 | 1,190 | 254 |
31 Mar 21 | 2,187 | 280 | 1,029 | 195 |
31 Dec 20 | 2,200 | 390 | 973 | 129 |
30 Sep 20 | 1,819 | 792 | 880 | 122 |
30 Jun 20 | 1,518 | 517 | 827 | 161 |
31 Mar 20 | 1,376 | 592 | 772 | 109 |
31 Dec 19 | 1,300 | 573 | 696 | 103 |
30 Sep 19 | 1,292 | 82 | 686 | 94 |
30 Jun 19 | 1,282 | 97 | 674 | 91 |
31 Mar 19 | 1,264 | 77 | 679 | 87 |
31 Dec 18 | 1,208 | -38 | 687 | 83 |
30 Sep 18 | 1,126 | -178 | 680 | -65 |
30 Jun 18 | 1,073 | -275 | 674 | -68 |
31 Mar 18 | 1,059 | -460 | 661 | 70 |
31 Dec 17 | 1,056 | -350 | 655 | 66 |
30 Sep 17 | 1,092 | -495 | 680 | 218 |
30 Jun 17 | 1,029 | -437 | 653 | 213 |
31 Mar 17 | 997 | -212 | 626 | 61 |
31 Dec 16 | 981 | -166 | 604 | 61 |
30 Sep 16 | 915 | -12 | 517 | 49 |
30 Jun 16 | 933 | -3 | 496 | 47 |
31 Mar 16 | 849 | 14 | 460 | 45 |
31 Dec 15 | 757 | 40 | 438 | 42 |
30 Sep 15 | 616 | -16 | 330 | 33 |
30 Jun 15 | 465 | -17 | 302 | 26 |
31 Mar 15 | 358 | -77 | 241 | 21 |
31 Dec 14 | 297 | -264 | 209 | 17 |
30 Sep 14 | 223 | -335 | 182 | 14 |
30 Jun 14 | 172 | -342 | 125 | 11 |
31 Mar 14 | 117 | -333 | 111 | 11 |
31 Dec 13 | 74 | -149 | 92 | 10 |
30 Sep 13 | 50 | -70 | 85 | 12 |
30 Jun 13 | 32 | -82 | 81 | 14 |
31 Mar 13 | 25 | -86 | 74 | 15 |
31 Dec 12 | 19 | -88 | 69 | 17 |
Quality Earnings: HZNP has a large one-off loss of $131.0M impacting its last 12 months of financial results to 30th June, 2023.
Growing Profit Margin: HZNP's current net profit margins (12%) are lower than last year (20.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HZNP has become profitable over the past 5 years, growing earnings by 32.8% per year.
Accelerating Growth: HZNP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: HZNP had negative earnings growth (-42.7%) over the past year, making it difficult to compare to the Biotechs industry average (-42.7%).
Return on Equity
High ROE: HZNP's Return on Equity (8.2%) is considered low.